Oracle deepens life sciences push with AI agents, real-world data analytics

Oracle is bolstering its presence in the life sciences sector through the enhancement of its AI-powered data platform. At the recent Oracle Health and Life Sciences Summit 2026, the company unveiled an expanded version of its Oracle Life Sciences AI Data Platform, now rebranded as Life Sciences Data Intelligence. This new iteration brings together AI agents, analytics tools, and natural-language data exploration, all tailored to expedite clinical research.

The platform, which was launched in January, is designed as a foundational data solution for life sciences organizations. It leverages generative AI and agentic reasoning to assist pharmaceutical, medical device, and research companies in accelerating drug development, clinical trials, safety monitoring, and commercialization efforts.

Building upon this initial launch, Oracle has now incorporated AI and real-world data capabilities specifically designed for life sciences workflows. This allows research teams to generate evidence, identify patients earlier in disease progression, and bolster clinical research efforts.

The platform unites a customer’s proprietary data with Oracle's extensive repository of real-world data, encompassing over 122 million longitudinal health records. This combination is facilitated through a secure, single platform, with robust oversight controls ensuring that de-identified patient data can be transformed into actionable insights. Oracle has also laid the groundwork for the integration of additional third-party datasets in the future.

Seema Verma, executive vice president and general manager of Oracle Health and Life Sciences, highlighted the platform's role in overcoming the challenges posed by fragmented data and disconnected workflows. She emphasized how Oracle’s unique offering of real-world data, coupled with domain-specific AI tools, enables researchers to conduct studies and explore data in natural language, accelerating the research process from discovery to commercialization.

The advanced analytics provided by the platform go beyond basic analytics tools, offering contextual guidance to researchers.

Nimita Limaye, Ph.D., research vice president at IDC, noted that Oracle is bridging the trust gap for researchers by combining governed real-world data, domain-trained AI capabilities, and advanced analytics within a single, connected environment. This approach transforms complex research questions into credible evidence more rapidly.

Oracle's Life Sciences Data Intelligence platform is designed to seamlessly integrate within Oracle’s broader technology ecosystem, including OCI, Oracle Life Sciences, Oracle Fusion Cloud applications, and Oracle Health solutions.

Oracle's commitment to advancing AI capabilities in healthcare and life sciences is evident through its focus on enterprise-scale, embedded intelligence across various clinical, operational, and research workflows. The company recently unveiled its next-generation electronic health record (EHR) equipped with AI and voice capabilities, aimed at making it easier for clinicians to navigate.

Additionally, Oracle has upgraded its AI-powered clinical agent to streamline professional fee coding, surface relevant patient context, and enhance inpatient nursing workflows. These advancements underscore Oracle's dedication to driving purposeful innovation in the industry, particularly in making smarter decisions across the therapeutic lifecycle.